SCHEMBL2177369

SCHEMBL2177369

CCOC(=O)C(=O)NCCCCNC(=O)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 1/20 0.60
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
PLA2G2A P14555 1/20 0.40
ALDH1A1 P00352 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
CYP2D6 P10635 1/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
EPHX1 P07099 3/20 0.38
ACHE P22303 1/20 0.38
MGAM O43451 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
GPR35 Q9HC97 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2180162 0.98 EGLN1 (0.58) EGLN1CA12CA1CA2CA9
SCHEMBL2176387 0.94 EGLN1 (0.62) EGLN1ALDH1A1SMN1; SMN2CYP2D6GAA
SCHEMBL13552393 0.92 EGLN1 (0.63) EGLN1MEN1KMT2ACA12CA1
SCHEMBL2032859 0.90 EGLN1 (0.61) EGLN1MEN1KMT2ACA12CA1
SCHEMBL11596790 0.90 EGLN1 (0.61) EGLN1MEN1KMT2ACA12CA1
SCHEMBL9408944 0.86 EGLN1 (0.57) EGLN1PLA2G2AEPHX1ACHEFAAH
SCHEMBL12495312 0.85 EGLN1 (0.65) EGLN1ALDH1A1SMN1; SMN2CYP2D6GAA
SCHEMBL11408936 0.84 EPHX1 (0.57) EGLN1PLA2G2AEPHX1ACHEFAAH
SCHEMBL15682714 0.84 EPHX1 (0.57) EGLN1PLA2G2AEPHX1ACHEFAAH
SCHEMBL2487820 0.84 EPHX1 (0.57) EGLN1PLA2G2AEPHX1ACHEFAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8765881-B2 Methods of making polydiorganosiloxane polyoxamide copolymers 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-07-01 US disclosed
EP-2519563-B1 METHODS OF MAKING POLYDIORGANOSILOXANE POLYOXAMIDE COPOLYMERS 3M INNOVATIVE PROPERTIES CO (US) 2013-11-06 EP disclosed
EP-2519563-A1 METHODS OF MAKING POLYDIORGANOSILOXANE POLYOXAMIDE COPOLYMERS 3M Innovative Properties Company (US) 2012-11-07 EP disclosed
US-20120271025-A1 METHODS OF MAKING POLYDIORGANOSILOXANE POLYOXAMIDE COPOLYMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-10-25 US disclosed
WO-2011082069-A1 METHODS OF MAKING POLYDIORGANOSILOXANE POLYOXAMIDE COPOLYMERS 3M INNOVATIVE PROPERTIES COMPANY (US) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120271025-A1 METHODS OF MAKING POLYDIORGANOSILOXANE POLYOXAMIDE COPOLYMERS PPOX, PARG, PAM EGLN1 322/4885MEN1 3144/4885KMT2A 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.